Literature DB >> 23771914

Molecular MR imaging of neovascular progression in the Vx2 tumor with αvβ3-targeted paramagnetic nanoparticles.

Anne H Schmieder1, Patrick M Winter, Todd A Williams, John S Allen, Grace Hu, Huiying Zhang, Shelton D Caruthers, Samuel A Wickline, Gregory M Lanza.   

Abstract

PURPOSE: To assess the dependence of neovascular molecular magnetic resonance (MR) imaging on relaxivity (r1) of αvβ3-targeted paramagnetic perfluorocarbon (PFC) nanoparticles and to delineate the temporal-spatial consistency of angiogenesis assessments for individual animals.
MATERIALS AND METHODS: Animal protocols were approved by the Washington University Animal Studies Committee. Proton longitudinal and transverse relaxation rates of αvβ3-targeted and nontargeted PFC nanoparticles incorporating gadolinium diethylenetrianime pentaacedic acid (Gd-DTPA) bisoleate (BOA) or gadolinium tetraazacyclododecane tetraacetic acid (Gd-DOTA) phosphatidylethanolamine (PE) into the surfactant were measured at 3.0 T. These paramagnetic nanoparticles were compared in 30 New Zealand White rabbits (four to six rabbits per group) 14 days after implantation of a Vx2 tumor. Subsequently, serial MR (3.0 T) neovascular maps were developed 8, 14, and 16 days after tumor implantation by using αvβ3-targeted Gd-DOTA-PE nanoparticles (n = 4) or nontargeted Gd-DOTA-PE nanoparticles (n = 4). Data were analyzed with analysis of variance and nonparametric statistics.
RESULTS: At 3.0 T, Gd-DTPA-BOA nanoparticles had an ionic r1 of 10.3 L · mmol(-1) · sec(-1) and a particulate r1 of 927000 L · mmol(-1) · sec(-1). Gd-DOTA-PE nanoparticles had an ionic r1 of 13.3 L · mmol(-1) · sec(-1) and a particulate r1 of 1 197000 L · mmol(-1) · sec(-1). Neovascular contrast enhancement in Vx2 tumors (at 14 days) was 5.4% ± 1.06 of the surface volume with αvβ3-targeted Gd-DOTA-PE nanoparticles and 3.0% ± 0.3 with αvβ3-targeted Gd-DTPA-BOA nanoparticles (P = .03). MR neovascular contrast maps of tumors 8, 14, and 16 days after implantation revealed temporally consistent and progressive surface enhancement (1.0% ± 0.3, 4.5% ± 0.9, and 9.3% ± 1.4, respectively; P = .0008), with similar time-dependent changes observed among individual animals.
CONCLUSION: Temporal-spatial patterns of angiogenesis for individual animals were followed to monitor longitudinal tumor progression. Neovasculature enhancement was dependent on the relaxivity of the targeted agent.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23771914      PMCID: PMC3721054          DOI: 10.1148/radiol.13120789

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  49 in total

1.  Synergistic effect of antiangiogenic nanotherapy combined with methotrexate in the treatment of experimental inflammatory arthritis.

Authors:  Hui-Fang Zhou; Grace Hu; Samuel A Wickline; Gregory M Lanza; Christine T N Pham
Journal:  Nanomedicine (Lond)       Date:  2010-09       Impact factor: 5.307

2.  Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations.

Authors:  Dushyant V Sahani; Sanjeeva P Kalva; Leena M Hamberg; Peter F Hahn; Christopher G Willett; Sanjay Saini; Peter R Mueller; Ting-Yim Lee
Journal:  Radiology       Date:  2005-03       Impact factor: 11.105

3.  Expression and localization of alpha v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma.

Authors:  F Carreiras; Y Denoux; C Staedel; M Lehmann; F Sichel; P Gauduchon
Journal:  Gynecol Oncol       Date:  1996-08       Impact factor: 5.482

4.  Granulocyte-macrophage and macrophage colony-stimulating factors differentially regulate alpha v integrin expression on cultured human macrophages.

Authors:  M O De Nichilo; G F Burns
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

5.  Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction.

Authors:  David F Meoli; Mehran M Sadeghi; Svetlana Krassilnikova; Brian N Bourke; Frank J Giordano; Donald P Dione; Haili Su; D Scott Edwards; Shuang Liu; Thomas D Harris; Joseph A Madri; Barry L Zaret; Albert J Sinusas
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

6.  Improved molecular imaging contrast agent for detection of human thrombus.

Authors:  Patrick M Winter; Shelton D Caruthers; Xin Yu; Sheng-Kwei Song; Junjie Chen; Brad Miller; Jeff W M Bulte; J David Robertson; Patrick J Gaffney; Samuel A Wickline; Gregory M Lanza
Journal:  Magn Reson Med       Date:  2003-08       Impact factor: 4.668

7.  Molecular photoacoustic tomography with colloidal nanobeacons.

Authors:  Dipanjan Pan; Manojit Pramanik; Angana Senpan; Xinmai Yang; Kwang H Song; Mike J Scott; Huiying Zhang; Patrick J Gaffney; Samuel A Wickline; Lihong V Wang; Gregory M Lanza
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

8.  Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging.

Authors:  Patrick M Winter; Shelton D Caruthers; Andrea Kassner; Thomas D Harris; Lori K Chinen; John S Allen; Elizabeth K Lacy; Huiying Zhang; J David Robertson; Samuel A Wickline; Gregory M Lanza
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

Review 9.  DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents.

Authors:  J P B O'Connor; A Jackson; G J M Parker; G C Jayson
Journal:  Br J Cancer       Date:  2007-01-09       Impact factor: 7.640

10.  Experiments on the cause of the rabbit carcinomas derived from virus-induced papillomas. II. Loss by the Vx2 carcinoma of the power to immunize hosts against the papilloma virus.

Authors:  P ROUS; J G KIDD; W E SMITH
Journal:  J Exp Med       Date:  1952-08       Impact factor: 14.307

View more
  20 in total

Review 1.  Nanoparticles for Cardiovascular Imaging and Therapeutic Delivery, Part 1: Compositions and Features.

Authors:  John C Stendahl; Albert J Sinusas
Journal:  J Nucl Med       Date:  2015-08-13       Impact factor: 10.057

2.  A targeted approach to cancer imaging and therapy.

Authors:  Chun Li
Journal:  Nat Mater       Date:  2014-02       Impact factor: 43.841

3.  Dual-therapy with αvβ3-targeted Sn2 lipase-labile fumagillin-prodrug nanoparticles and zoledronic acid in the Vx2 rabbit tumor model.

Authors:  Alison K Esser; Anne H Schmieder; Michael H Ross; Jingyu Xiang; Xinming Su; Grace Cui; Huiying Zhang; Xiaoxia Yang; John S Allen; Todd Williams; Samuel A Wickline; Dipanjan Pan; Gregory M Lanza; Katherine N Weilbaecher
Journal:  Nanomedicine       Date:  2015-10-27       Impact factor: 5.307

4.  Synergy between surface and core entrapped metals in a mixed manganese-gadolinium nanocolloid affords safer MR imaging of sparse biomarkers.

Authors:  Kezheng Wang; Dipanjan Pan; Anne H Schmieder; Angana Senpan; Dennis E Hourcade; Christine T N Pham; Lynne M Mitchell; Shelton D Caruthers; Grace Cui; Samuel A Wickline; Baozhong Shen; Gregory M Lanza
Journal:  Nanomedicine       Date:  2015-01-31       Impact factor: 5.307

5.  Impact of Chemoembolic Regimen on Immune Cell Recruitment and Immune Checkpoint Marker Expression following Transcatheter Arterial Chemoembolization in a VX2 Rabbit Liver Tumor Model.

Authors:  Antonia M Berz; Jessica G Santana; Simon Iseke; Moritz Gross; Vasily Pekurovsky; Fabian Laage Gaupp; Lynn J Savic; Tabea Borde; Luzie A Gottwald; Anne Marie Boustani; Bernhard Gebauer; MingDe Lin; Xuchen Zhang; Todd Schlachter; David C Madoff; Julius Chapiro
Journal:  J Vasc Interv Radiol       Date:  2022-03-26       Impact factor: 3.682

Review 6.  Molecular imaging of the tumor microenvironment for precision medicine and theranostics.

Authors:  Marie-France Penet; Balaji Krishnamachary; Zhihang Chen; Jiefu Jin; Zaver M Bhujwalla
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

7.  Application of a hemolysis assay for analysis of complement activation by perfluorocarbon nanoparticles.

Authors:  Christine T N Pham; Dennis G Thomas; Julia Beiser; Lynne M Mitchell; Jennifer L Huang; Angana Senpan; Grace Hu; Mae Gordon; Nathan A Baker; Dipanjan Pan; Gregory M Lanza; Dennis E Hourcade
Journal:  Nanomedicine       Date:  2013-11-08       Impact factor: 5.307

8.  GRPR-targeted Protein Contrast Agents for Molecular Imaging of Receptor Expression in Cancers by MRI.

Authors:  Fan Pu; Jingjuan Qiao; Shenghui Xue; Hua Yang; Anvi Patel; Lixia Wei; Khan Hekmatyar; Mani Salarian; Hans E Grossniklaus; Zhi-Ren Liu; Jenny J Yang
Journal:  Sci Rep       Date:  2015-11-18       Impact factor: 4.379

9.  Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a lipase-cleavable Sn 2 taxane phospholipid prodrug using α(v)β₃-targeted theranostic nanoparticles.

Authors:  Dipanjan Pan; Anne H Schmieder; Kezheng Wang; Xiaoxia Yang; Angana Senpan; Grace Cui; Kendall Killgore; Benjamin Kim; John S Allen; Huiying Zhang; Shelton D Caruthers; Baozhong Shen; Samuel A Wickline; Gregory M Lanza
Journal:  Theranostics       Date:  2014-03-11       Impact factor: 11.556

Review 10.  Nanoparticles for imaging: top or flop?

Authors:  Fabian Kiessling; Marianne E Mertens; Jan Grimm; Twan Lammers
Journal:  Radiology       Date:  2014-10       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.